Corporate Overview

Novira Therapeutics Inc. is focused on the discovery and development of first-in-class therapies for the treatment of chronic hepatitis B (CHB) infection, a global disease with a high level of unmet medical need.

Novira Therapeutics was acquired by Johnson & Johnson in December 2015 and is now part of the Janssen Pharmaceutical Companies.